Literature DB >> 17917967

Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2.

Anja Vales1, Rudin Kondo, Karl J Aichberger, Matthias Mayerhofer, Birgit Kainz, Wolfgang R Sperr, Christian Sillaber, Ulrich Jäger, Peter Valent.   

Abstract

Vascular endothelial growth factor (VEGF) is produced in neoplastic cells in various myeloid neoplasms and may act as an autocrine growth-regulator. We have examined the expression of five VEGF receptors (VEGR1/Flt-1, VEGFR2/KDR, Flt-4, neuropilin-1 = NRP-1, NRP-2) in leukemic cells obtained from patients with acute myeloid leukemia (n = 28), chronic myeloid leukemia (n = 14), chronic eosinophilic leukemia (n = 3), chronic myelomonocytic leukemia (n = 9), or mast cell leukemia/systemic mastocytosis (n = 3) as well as in respective cell lines. Expression of VEGFR mRNA was analyzed by RT-PCR, and expression of VEGFR protein by immunocytochemistry. In most patients, leukemic cells expressed NRP-1 mRNA and NRP-2 mRNA independent of the type of disease. By contrast, transcripts for Flt-1, KDR, and Flt-4 were expressed variably without a clear correlation to the type of leukemia. Expression of VEGF receptors was also demonstrable at the protein level in all cases tested. In conclusion, neoplastic cells in myeloid leukemias frequently express VEGFR including NRP-1 and NRP-2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917967     DOI: 10.1080/10428190701534424

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  13 in total

1.  Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells.

Authors:  Thomas W Grunt; Alexandra Hebar; Sylvia Laffer; Renate Wagner; Barbara Peter; Harald Herrmann; Alexandra Graf; Martin Bilban; Martin Posch; Gregor Hoermann; Matthias Mayerhofer; Gregor Eisenwort; Christoph C Zielinski; Edgar Selzer; Peter Valent
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

2.  Targeting neuropilin-1 in human leukemia and lymphoma.

Authors:  Katja Karjalainen; Diana E Jaalouk; Carlos E Bueso-Ramos; Amado J Zurita; Akihiko Kuniyasu; Bedrich L Eckhardt; Frank C Marini; Benjamin Lichtiger; Susan O'Brien; Hagop M Kantarjian; Jorge E Cortes; Erkki Koivunen; Wadih Arap; Renata Pasqualini
Journal:  Blood       Date:  2010-11-09       Impact factor: 22.113

Review 3.  Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance.

Authors:  Ridwan Islam; Juhi Mishra; Sanika Bodas; Sreyashi Bhattacharya; Surinder K Batra; Samikshan Dutta; Kaustubh Datta
Journal:  Cancer Metastasis Rev       Date:  2022-07-01       Impact factor: 9.237

4.  Investigation of a novel biomarker, neuropilin-1, and its application for poor prognosis in acute myeloid leukemia patients.

Authors:  Jianqiang Zhao; Liufang Gu; Chengliang Li; Weiguo Ma; Zengfeng Ni
Journal:  Tumour Biol       Date:  2014-04-16

5.  Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab.

Authors:  Gerald W Prager; Eva-Maria Lackner; Maria-Theresa Krauth; Matthias Unseld; Marina Poettler; Sylvia Laffer; Sabine Cerny-Reiterer; Wolfgang Lamm; Gabriela V Kornek; Bernd R Binder; Christoph C Zielinski; Peter Valent
Journal:  Mol Oncol       Date:  2010-01-07       Impact factor: 6.603

6.  Neuropilin-2 expression promotes TGF-β1-mediated epithelial to mesenchymal transition in colorectal cancer cells.

Authors:  Camille Grandclement; Jean René Pallandre; Séverine Valmary Degano; Erika Viel; Adeline Bouard; Jérémy Balland; Jean-Paul Rémy-Martin; Benoit Simon; Alain Rouleau; Wilfrid Boireau; Michael Klagsbrun; Christophe Ferrand; Christophe Borg
Journal:  PLoS One       Date:  2011-07-01       Impact factor: 3.240

7.  Significance of neuropilin-1 expression in acute myeloid leukemia.

Authors:  Tarif H Sallam; Manal A Shams Eldin El Telbany; Hanan M Mahmoud; Mutea A Iskander
Journal:  Turk J Haematol       Date:  2013-09-05       Impact factor: 1.831

8.  Prognostic Impact of Neuropilin-1 Expression in Egyptian Children with B-lineage Acute Lymphoblastic Leukemia.

Authors:  Adel A Hagag; Nahla A Nosair
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-01-01       Impact factor: 2.576

9.  Vasculogenic mimicry of HT1080 tumour cells in vivo: critical role of HIF-1α-neuropilin-1 axis.

Authors:  Roli M Misra; Manmohan S Bajaj; Vaijayanti P Kale
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

10.  Neuropilins: a new target for cancer therapy.

Authors:  Camille Grandclement; Christophe Borg
Journal:  Cancers (Basel)       Date:  2011-04-08       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.